Pseudoephedrine/loratadine: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 14:01, 14 July 2011 editAnypodetos (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 edits Move interactions to pseudoephedrine; remove merge template← Previous edit		Latest revision as of 07:32, 22 December 2024 edit undoWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,153 edits rank
(43 intermediate revisions by 32 users not shown)
Line 1:		Line 1:
			{{Short description\|Allergy medicine}}
	{{drugbox
			{{Use dmy dates\|date=July 2024}}
⚫	\| verifiedrevid = ~~437095062~~
			{{cs1 config \|name-list-style=vanc \|display-authors=6}}
⚫	\| type = combo
			{{Drugbox
⚫	\| component1 = Pseudoephedrine
		⚫	\| verifiedrevid = 439439973
⚫	\| class1 = ]
		⚫	\| type = combo
⚫	\| component2 = Loratadine

⚫	\| class2 = ]
			<!--Combo data-->
⚫	\| CAS_number =
		⚫	\| component1 = Pseudoephedrine
⚫	\| ATC_prefix = R01
		⚫	\| class1 = ]
⚫	\| ATC_suffix = BA52
		⚫	\| component2 = Loratadine
	\| PubChem =
		⚫	\| class2 = ]
	\| DrugBank =

	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
			<!--Clinical data-->
	\| pregnancy_US = B
			\| tradename = Claritin-D, others
⚫	\| pregnancy_category=
			\| Drugs.com = {{Drugs.com\|parent\|claritin-d}}
⚫	\| legal_AU = <!-- ~~Unscheduled /~~ S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
	\| ~~legal_CA~~ = <!-- / ~~Schedule I, II, III, IV, V, VI, VII, VIII~~ -->		\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
		⚫	\| pregnancy_category =
	\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
		⚫	\| routes_of_administration = ]
⚫	\| ~~legal_US~~ = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
		⚫	\| ATC_prefix = R01
	\| legal_status = ]
		⚫	\| ATC_suffix = BA52
⚫	\| routes_of_administration = ~~Oral~~

		⚫	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
		⚫	\| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
			\| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
			\| legal_US = OTC
			\| legal_US_comment = <ref name="Claritin-D FDA label">{{cite web \| title=Claritin-D 12 hour- loratadine and pseudoephedrine sulfate tablet, extended release \| website=DailyMed \| date=30 November 2023 \| url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7125705-01ff-4418-8c53-9209c2bbb484 \| access-date=8 July 2024}}</ref>
			\| legal_status =

			<!--Identifiers-->
		⚫	\| CAS_number = 156098-07-6

			<!--Chemical data-->
	}}		}}

	'''Pseudoephedrine/loratadine''' ~~(trade~~ ~~names~~ '''Claritin-D''', ~~'''Clarinase'''~~, ~~'''Clarinase Repetabs''')~~ is an orally administered ~~drug~~ combination for the treatment of ] and the ]. ], one of the naturally occurring alkaloids of ], is a ] used as a ]. It produces ~~its~~ decongestant effect ~~facilitating~~ ] ~~and~~ ~~shrinkage~~ of ~~congested~~ ~~mucosa~~ in upper respiratory areas. ] is a long acting ] that is less ] than older substances of ~~the~~ type.		'''Pseudoephedrine/loratadine''', sold under the brand name '''Claritin-D''' among others, is an orally administered ] used for the treatment of ] (hay fever) and the ].<ref name="Claritin-D FDA label" /> ], one of the naturally occurring alkaloids of ], is a ] used as a ].{{medcn\|date=July 2024}} It produces a decongestant effect that is facilitated by the ] in the mucosal capillaries of the upper respiratory areas.{{medcn\|date=July 2024}} ] is a long-acting ] (H<sub>1</sub> histamine antagonist) that is less ] than older substances of its type.{{medcn\|date=July 2024}}

			In 2022, it was the 289th most commonly prescribed medication in the United States, with more than 500,000 prescriptions.<ref>{{cite web \| title=The Top 300 of 2022 \| url=https://clincalc.com/DrugStats/Top300Drugs.aspx \| website=ClinCalc \| access-date=30 August 2024 \| archive-date=30 August 2024 \| archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx \| url-status=live }}</ref><ref>{{cite web \| title = Loratadine; Pseudoephedrine Drug Usage Statistics, United States, 2013 - 2022 \| website = ClinCalc \| url = https://clincalc.com/DrugStats/Drugs/LoratadinePseudoephedrine \| access-date = 30 August 2024 }}</ref>
	==Indications and usage==

	Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, ], ], ] and ].
			==Medical uses==
			Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, ], ], ], and ].<ref name="Claritin-D FDA label" /><ref>{{cite book\|title=Austria-Codex\|at=Clarinase 5 mg/120 mg Retardtabletten\| veditors = Haberfeld H \|publisher=Österreichischer Apothekerverlag\|location=Vienna\|year=2009\|edition=2009/2010\|isbn=978-3-85200-196-8\|language=German}}</ref>

	==Composition==		==Composition==

	===Clarinase Repetabs===		===Clarinase Repetabs===
			{{unreferenced section\|date=July 2024}}
	A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.		A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.

Line 35:		Line 51:

	===Interactions===		===Interactions===
			{{unreferenced section\|date=July 2024}}
	When sympathomimetics are given to patients receiving ]s (MAO inhibitors), hypertensive reactions, including ] may occur.		When sympathomimetics are given to patients receiving ]s (MAO inhibitors), hypertensive reactions, including ] may occur.

	===Adverse effects===		===Adverse effects===
			{{unreferenced section\|date=July 2024}}
	During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of ] and dry mouth, both of which were commonly reported.		During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of ] and dry mouth, both of which were commonly reported.

	===Contraindications===		===Contraindications===
			{{unreferenced section\|date=July 2024}}
	~~Clarinase~~ is contraindicated in ~~patients~~ receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in ~~patients~~ with narrow angle ], urinary retention, severe ], severe ] and ].		Pseudoephedrine/loratadine is contraindicated in people receiving ] therapy or within 14 days of discontinuing such treatment and in people with narrow angle ], urinary retention, severe ], severe ] and ].

			== Society and culture ==
			=== Brand names ===
			It is sold under various brand names including Claritin-D, Clarinase, Clarinase Repetabs, Lorinase, Rhinos SR, and Allerclear-D.

	==References==		==References==
			{{reflist}}
	* Drugs.com:
	* Israel Ministry of Health:
	* {{cite book\|title=Austria-Codex\|editor=Haberfeld, H\|publisher=Österreichischer Apothekerverlag\|location=Vienna\|year=2009\|edition=2009/2010\|isbn=3-85200-196-X\|language=German}}

	{{Nasal preparations}}		{{Nasal preparations}}
			{{Portal bar \| Medicine}}
			{{Authority control}}

			{{DEFAULTSORT:Pseudoephedrine Loratadine}}
	]		]
	]
	]		]
	]		]

	]

Latest revision as of 07:32, 22 December 2024

Allergy medicine

Pharmaceutical compound

Pseudoephedrine/loratadine
Combination of
Pseudoephedrine	Sympathomimetic
Loratadine	H₁ antagonist
Clinical data
Trade names	Claritin-D, others
AHFS/Drugs.com	claritin-d
Routes of administration	By mouth
ATC code	R01BA52 (WHO)
Legal status
Legal status	US: OTC
Identifiers
CAS Number	156098-07-6
(verify)

Pseudoephedrine/loratadine, sold under the brand name Claritin-D among others, is an orally administered combination medication used for the treatment of allergic rhinitis (hay fever) and the common cold. Pseudoephedrine, one of the naturally occurring alkaloids of ephedra, is a sympathomimetic used as a decongestant. It produces a decongestant effect that is facilitated by the vasoconstriction in the mucosal capillaries of the upper respiratory areas. Loratadine is a long-acting antihistamine (H₁ histamine antagonist) that is less sedating than older substances of its type.

In 2022, it was the 289th most commonly prescribed medication in the United States, with more than 500,000 prescriptions.

Medical uses

Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation.

Composition

Clarinase Repetabs

This section does not cite any sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (July 2024) (Learn how and when to remove this message)

A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.

Interactions, adverse effects and contraindications

Interactions, adverse effects and contraindications are described in more detail in the articles about pseudoephedrine and loratadine.

Interactions

When sympathomimetics are given to patients receiving monoamine oxidase inhibitors (MAO inhibitors), hypertensive reactions, including hypertensive crises may occur.

Adverse effects

During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported.

Contraindications

Pseudoephedrine/loratadine is contraindicated in people receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in people with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.

Society and culture

Brand names

It is sold under various brand names including Claritin-D, Clarinase, Clarinase Repetabs, Lorinase, Rhinos SR, and Allerclear-D.

References

^ "Claritin-D 12 hour- loratadine and pseudoephedrine sulfate tablet, extended release". DailyMed. 30 November 2023. Retrieved 8 July 2024.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Loratadine; Pseudoephedrine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
Haberfeld H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. Clarinase 5 mg/120 mg Retardtabletten. ISBN 978-3-85200-196-8.

Decongestants and other nasal preparations (R01)

Topical

Sympathomimetics, plain	Amidephrine Cyclopentamine Ephedrine Epinephrine Fenoxazoline Iproheptine Levmetamfetamine Methylephedrine Metizoline Naphazoline Oxymetazoline Phenylephrine Propylhexedrine Tetryzoline Tramazoline Tuaminoheptane Tymazoline Xylometazoline
Antiallergic agents, excluding corticosteroids	Spaglumic acid histamine antagonists (Levocabastine Antazoline Thonzylamine) mast cell stabilizer (some are also antihistamines) (Cromoglicic acid Nedocromil Azelastine Olopatadine Lodoxamide)
Corticosteroids	Beclometasone dipropionate Betamethasone Budesonide Ciclesonide Dexamethasone Flunisolide Fluticasone (Fluticasone furoate, Fluticasone propionate) Mometasone furoate Prednisolone Tixocortol Triamcinolone Triamcinolone acetonide
Other nasal preparations	Cafaminol Calcium hexamine thiocyanate Eucalyptus oil Framycetin Hexamidine Hyaluronan Ipratropium bromide Mupirocin Retinol Ritiometan Saline water
Combination products	Olopatadine/mometasone

Systemic use:
Sympathomimetics

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Portal:

Medicine

Categories: